ID   SUM149-Luc/MA2
AC   CVCL_DH46
SY   MA2
DR   cancercelllines; CVCL_DH46
DR   GEO; GSM1463861
DR   GEO; GSM1463864
DR   Wikidata; Q54970831
RX   PubMed=25279830;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Pro724Leufs*12 (c.2169delT) (p.Asn723fs*13) (2288delT); Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3373; EP300; Simple; c.4025+26_4025+30 (c.5224+28del3); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (from parent cell line).
CC   Transfected with: UniProtKB; P08659; Firefly luciferase.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4001; Breast inflammatory carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_DH44 ! SUM149-Luc
SX   Female
AG   40Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 14
//
RX   PubMed=25279830; DOI=10.1371/journal.pone.0109487;
RA   Singh B., Shamsnia A., Raythatha M.R., Milligan R.D., Cady A.M.,
RA   Madan S., Lucci A.;
RT   "Highly adaptable triple-negative breast cancer cells as a functional
RT   model for testing anticancer agents.";
RL   PLoS ONE 9:E109487-E109487(2014).
//